<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521508</url>
  </required_header>
  <id_info>
    <org_study_id>0608118</org_study_id>
    <secondary_id>2007-A00129-44</secondary_id>
    <secondary_id>DGS 2007-0184</secondary_id>
    <nct_id>NCT00521508</nct_id>
  </id_info>
  <brief_title>Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy</brief_title>
  <official_title>Role of CD4+CD25+FoxP3+ Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Along structural IgA abnormalities, hyperproduction of IgA is thought to play a role in the
      pathogenesis of primary IgA nephropathy. CD4+CD25+Fox3P regulatory T cells are instrumental
      in suppressing adaptative immune responses, including B cells production of immunoglobulins.
      We, the researchers at Centre Hospitalier Universitaire de Saine Etienne, will test the
      hypothesis that IgA production in patients with IgA nephropathy is dysregulated because of a
      quantitative and/or qualitative defect of CD4+CD25+FoxP3+ regulatory T cells.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion averages of cells CD4+CD25+CD127 low T in peripheral blood</measure>
    <time_frame>inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>average relative expression of genes FoxP3, CTLA4, GITR, IL10, TGF-B, OX40, TIM-1, and TIM-3</measure>
    <time_frame>inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Glomerulonephritis, IGA</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient affected by Berger's disease confirmed by renal biopsy with increased rate of Ig A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient affected by Berger's disease with normal rate of Ig A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gene transcription and cytometry</intervention_name>
    <description>samply of 30 ml of blood</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathogenesis of Berger's disease confirmed by renal biopsy

          -  Glomerular filtration &gt; 60 ml/min/1,73m2

          -  Written informed consent

          -  Patient affiliated to social insurance

        Exclusion Criteria:

          -  Immunosuppressor treatment within 6 months before the study inclusion

          -  Clinical infection within 2 months before the study inclusion

          -  C-reactive protein (CRP) &gt; 10 mgL-1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe MARIAT, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Unit Hôpital Nord CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Laville M, Alamartine E. Treatment options for IgA nephropathy in adults: a proposal for evidence-based strategy. Nephrol Dial Transplant. 2004 Aug;19(8):1947-51. Epub 2004 May 25.</citation>
    <PMID>15161954</PMID>
  </reference>
  <reference>
    <citation>Mariat C, Sánchez-Fueyo A, Alexopoulos SP, Kenny J, Strom TB, Zheng XX. Regulation of T cell dependent immune responses by TIM family members. Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1681-5. Review.</citation>
    <PMID>16147532</PMID>
  </reference>
  <reference>
    <citation>Mariat C Degauque N et al. TIM-1 strengthens Th-1 polarization and weakens CD4+CD25 T cells. Am J Transplant 6(suppl 2): 557, 2006</citation>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <last_update_submitted>September 28, 2010</last_update_submitted>
  <last_update_submitted_qc>September 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clément CAILLAUX</name_title>
    <organization>CHU Saint-Etienne</organization>
  </responsible_party>
  <keyword>IgA</keyword>
  <keyword>kidney</keyword>
  <keyword>Berger'disease</keyword>
  <keyword>regulatory T cells</keyword>
  <keyword>pathogenesis of Berger's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

